5,640 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Purchased by Congress Wealth Management LLC DE

Congress Wealth Management LLC DE purchased a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) in the fourth quarter, Holdings Channel reports. The institutional investor purchased 5,640 shares of the company’s stock, valued at approximately $222,000.

Several other large investors also recently made changes to their positions in CRSP. Magnetar Financial LLC bought a new stake in shares of CRISPR Therapeutics in the 4th quarter worth approximately $359,000. Capital Market Strategies LLC bought a new position in shares of CRISPR Therapeutics in the fourth quarter valued at $461,000. KBC Group NV lifted its position in shares of CRISPR Therapeutics by 2,047.4% during the 4th quarter. KBC Group NV now owns 60,514 shares of the company’s stock valued at $2,382,000 after acquiring an additional 57,696 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of CRISPR Therapeutics by 3.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock worth $47,383,000 after acquiring an additional 35,196 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after acquiring an additional 599,304 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Down 2.8 %

CRISPR Therapeutics stock opened at $36.99 on Monday. The company has a market capitalization of $3.17 billion, a P/E ratio of -8.46 and a beta of 1.77. CRISPR Therapeutics AG has a 1-year low of $36.52 and a 1-year high of $68.39. The firm’s fifty day simple moving average is $43.10 and its 200-day simple moving average is $45.17.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, equities research analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Ratings Changes

CRSP has been the topic of a number of analyst reports. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research note on Friday, March 21st. TD Cowen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price target on the stock in a report on Wednesday, February 12th. The Goldman Sachs Group decreased their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Stifel Nicolaus cut their target price on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research note on Thursday, February 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics has an average rating of “Hold” and a consensus target price of $73.11.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares in the company, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John Greene acquired 7,000 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, February 26th. The stock was purchased at an average price of $44.85 per share, with a total value of $313,950.00. Following the completion of the purchase, the director now directly owns 7,000 shares of the company’s stock, valued at $313,950. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 32,381 shares of company stock valued at $1,608,243. Corporate insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.